Free Trial

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Price Target at $47.89

Arrowhead Pharmaceuticals logo with Medical background

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given an average rating of "Moderate Buy" by the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $47.89.

Several research firms have issued reports on ARWR. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arrowhead Pharmaceuticals in a report on Thursday, June 20th. Morgan Stanley lowered their price objective on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an "equal weight" rating on the stock in a report on Monday, May 13th. Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, June 3rd. The Goldman Sachs Group began coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They set a "neutral" rating and a $31.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $90.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, June 11th.

Check Out Our Latest Report on Arrowhead Pharmaceuticals

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the firm's stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the sale, the director now owns 30,205 shares of the company's stock, valued at $704,078.55. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 4.50% of the company's stock.


Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Washington Trust Advisors Inc. purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth $25,000. Neo Ivy Capital Management purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter worth about $41,000. Quest Partners LLC acquired a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $45,000. Friedenthal Financial purchased a new position in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $51,000. Finally, Van ECK Associates Corp grew its holdings in shares of Arrowhead Pharmaceuticals by 22.9% in the fourth quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company's stock valued at $73,000 after purchasing an additional 447 shares in the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

Arrowhead Pharmaceuticals Stock Down 1.4 %

Shares of ARWR stock traded down $0.37 during mid-day trading on Tuesday, hitting $26.87. 1,094,754 shares of the stock were exchanged, compared to its average volume of 1,339,066. Arrowhead Pharmaceuticals has a 52-week low of $20.67 and a 52-week high of $39.83. The firm has a fifty day moving average of $24.15 and a 200 day moving average of $28.34. The company has a market cap of $3.34 billion, a PE ratio of -6.49 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. During the same period last year, the business earned $0.45 earnings per share. Arrowhead Pharmaceuticals's revenue for the quarter was down 100.0% on a year-over-year basis. Equities analysts predict that Arrowhead Pharmaceuticals will post -3.05 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

(Get Free Report

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

See Also

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

→ Central Bank Gold Heist In Progress (From Colonial Metals) (Ad)

Should you invest $1,000 in Arrowhead Pharmaceuticals right now?

Before you consider Arrowhead Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arrowhead Pharmaceuticals wasn't on the list.

While Arrowhead Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

4 Best Tech Stocks to Own in 2024

4 Best Tech Stocks to Own in 2024

In this video, we explore the recent selloff and rotation of investments from NVDA to other Magnificent 7 stocks. Our analysts highlight four standout stocks—Amazon, Apple, Meta, and Alphabet.

Related Videos

The Best Single Stock to Own for 5 Years
NVIDIA Tops Microsoft and Apple for Most Valuable Company
3 Strong Buy Stocks for a Summer Surge

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines